Aukera Therapeutics GmbH
Aukera Therapeutics develops first-in-class, fully selective mTORC1 inhibitor therapeutics to address rare neurological disorders and cancers. The preclinical-stage biotech spin-off from the University of Basel uses computational and experimental protein design to discover and optimize drug candidates against complex mTOR biology. Its pipeline centers on a lead mTORC1-selective program progressing through preclinical candidate development. Aukera operates as a B2B-oriented biotech seeking collaborations with pharmaceutical and biotech partners to advance candidates into clinical development.
Aukera Therapeutics GmbH
Aukera Therapeutics develops first-in-class, fully selective mTORC1 inhibitor therapeutics to address rare neurological disorders and cancers. The preclinical-stage biotech spin-off from the University of Basel uses computational and experimental protein design to discover and optimize drug candidates against complex mTOR biology. Its pipeline centers on a lead mTORC1-selective program progressing through preclinical candidate development. Aukera operates as a B2B-oriented biotech seeking collaborations with pharmaceutical and biotech partners to advance candidates into clinical development.